SCHEDULE: Millennium Management Discloses 1.3% Stake in Pyxis Oncology

Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander reported a 1.3% beneficial ownership stake in Pyxis Oncology, Inc. as of September 30, 2025.

Summary

• Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander collectively reported beneficial ownership of 818,134 shares of Pyxis Oncology, Inc. Common Stock.
• This ownership represents 1.3% of the outstanding class of securities.
• The reporting persons share both voting and dispositive power over all 818,134 beneficially owned shares.
• This filing is an Amendment No. 1 to a Schedule 13G, indicating an update to a previous ownership disclosure.

Sentiment

Score: 5

Explanation: A Schedule 13G filing is a factual disclosure of ownership and does not inherently convey positive or negative sentiment regarding the issuer's performance or prospects. The 1.3% stake is not a controlling interest and represents a routine institutional holding.

Future Outlook

NA

Industry Context

This filing reflects a routine disclosure of beneficial ownership by an institutional investor group in a biotechnology company. Such disclosures are common and provide transparency regarding significant holdings in public companies, though a 1.3% stake is not a controlling interest.

Stakeholder Impact

• Shareholders: Provides transparency regarding institutional ownership, confirming Millennium Management's continued or adjusted stake in Pyxis Oncology.

Key Dates

Keywords

Pyxis Oncology, Millennium Management, Israel A. Englander, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor